ClinicalTrials.gg
CompletedNCT05304767Updated Jul 31, 2026

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 94 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
5th of 20
290 · median 178
Started
2022
with 1 other
Phase 3
14 of 20
4 open now
Registered
7th of 20
by date
Lead sponsor
7 of 20
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 5th largest by enrollment, is one of 2 that started in 2022, is one of 14 in phase 3, and was the 7th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) in subjects with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged ≥18 to \<66 years at the time of randomization of Study KAR-012
  2. Subject has successfully completed the treatment period of Study KAR-012
  3. Subject has been compliant with the procedures in Study KAR-012 (in the Investigator's judgement)
  4. Subject has been compliant with their background antipsychotic drug in Study KAR-012 in the opinion of the Investigator and based on subject and informant reporting Note: Subjects are required to remain on the same appropriate approved APD as in Study KAR-012 and should stay on that same dose throughout the study.
  5. Subject is capable of providing signed Form before any study assessments will be performed
  6. Subject resides in a stable living situation, in the opinion of the Investigator
  7. Subject has identified a reliable informant/caregiver willing and able to assist with study activities as needed throughout the subject's participation in the study. The informant can complete the study visits assessments via phone (as per local regulations). In Bulgaria, the informant needs to be physically present at all study visits where the Investigator determines that his/her input would be beneficial.
  8. Women of (WOCP), or men whose sexual partners are WOCP, must be able and willing to use at least 1 highly effective method of during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of the study drug. A female subject is considered to be a WOCP after menarche and until she is in a state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

Exclusion criteria

Exclusion Criteria:

  1. Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or Columbia-Suicide Severity Rating Scale (C-SSRS) as confirmed by the following:

    1. Subject answers "Yes" to "suicidal ideation" Item 4 (active suicidal ideation with some intent to act, without a specific plan) or Item 5 (active suicidal ideation with a specific plan and intent) on the C-SSRS
    2. Non-suicidal self-injurious behavior is not exclusionary
  2. Any abnormalities, including any finding(s) from , or laboratory test at Visit 6, and the physical examination, vital signs, at the EOT visit of Study KAR-012 that the Investigator, in consultation with the Medical Monitor are considered to jeopardize the safety of the subject
  3. Female subject is pregnant
  4. If, in the opinion of the Investigator (and/or Sponsor/ Medical Monitor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator (and/or Sponsor /Medical Monitor), may compromise the safety of the subject or affect their ability to adhere to the protocol visit schedule or study requirements
  5. Risk of violent or destructive behavior as per Investigator's judgement
  6. Subjects participating in another drug or device trial or planning on participating in another clinical trial during the study
  7. History or high risk of urinary retention, gastric retention, or narrow angle glaucoma as evaluated by the Investigator
  8. Subject is taking, or plans to take while in the study, any prohibited concomitant medication
  9. For all male subjects only, any one of the following:

    1. History of bladder stones
    2. History of recurrent urinary tract infections
    3. Serum prostate specific antigen (PSA) >10 ng/mL
    4. An International Prostate Symptom Score (IPSS) of 5 (almost always) on either item 1, 3, 5, or 6
    5. A sum of scores on IPSS items 1, 3, 5, and 6 of ≥9 Note: IPSS will be required only for male subjects ≥ 45 years of age. Subjects already enrolled in the study who do not have available PSA values from Study KAR-012 for baseline value use in Study CN012-0009, will have these assessments at their next clinic visit planned after re-consenting to determine current eligibility.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    Drug: KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From initial dose to safety follow-up visit (54 weeks) or early termination

Secondary outcomes

  1. Incidence of serious treatment-emergent adverse events (TEAEs)

    Time frame: From initial dose to safety follow-up visit (54 weeks) or early termination

  2. Incidence of TEAEs leading to discontinuation of study drug

    Time frame: From initial dose to safety follow-up visit (54 weeks) or early termination

07

Study locations

94 sites
  • Local Institution - 161
    Phoenix, Arizona 85012, United States
  • Local Institution - 175
    Little Rock, Arkansas 72204, United States
  • Local Institution - 112
    Little Rock, Arkansas 72211, United States
  • Local Institution - 146
    Anaheim, California 92805, United States
  • Local Institution - 130
    Bellflower, California 90706, United States
  • Local Institution - 110
    Cerritos, California 90703, United States
  • Local Institution - 167
    Culver City, California 90230, United States
  • Local Institution - 127
    Garden Grove, California 92845, United States
  • Local Institution - 152
    La Habra, California 90631-3842, United States
  • Local Institution - 126
    Lafayette, California 94549, United States
  • Local Institution - 131
    Lemon Grove, California 91945-2956, United States
  • Local Institution - 181
    Oceanside, California 92056, United States
  • Local Institution - 150
    Orange, California 92868, United States
  • Local Institution - 170
    Pico Rivera, California 90660, United States
  • Local Institution - 144
    Riverside, California 92506, United States
  • Local Institution - 164
    Stanford, California 94305, United States
  • Local Institution - 109
    Torrance, California 90504, United States
  • Local Institution - 186
    Coral Gables, Florida 33134, United States
  • Local Institution - 182
    Hialeah, Florida 33012, United States
  • Local Institution - 133
    Hialeah, Florida 33016-1814, United States
  • Local Institution - 105
    Lauderhill, Florida 33319-4985, United States
  • Local Institution - 145
    Miami, Florida 33122-1335, United States
  • Local Institution - 171
    Miami, Florida 33166, United States
  • Local Institution - 173
    Miami Lakes, Florida 33014, United States
  • Local Institution - 153
    Miami Lakes, Florida 33016, United States
  • Local Institution - 156
    Pembroke Pines, Florida 33025, United States
  • Local Institution - 155
    Tampa, Florida 33629, United States
  • Local Institution - 136
    Atlanta, Georgia 30303-3031, United States
  • Local Institution - 111
    Atlanta, Georgia 30328, United States
  • Local Institution - 192
    Atlanta, Georgia 30331, United States
  • Local Institution - 138
    Decatur, Georgia 30030, United States
  • Local Institution - 169
    Marietta, Georgia 30060, United States
  • Local Institution - 151
    Chicago, Illinois 60640, United States
  • Local Institution - 166
    Gaithersburg, Maryland 20877, United States
  • Local Institution - 187
    Boston, Massachusetts 02118, United States
  • Local Institution - 129
    St Louis, Missouri 63128, United States
  • Local Institution - 178
    St Louis, Missouri 63141, United States
  • Local Institution - 174
    Omaha, Nebraska 68144, United States
  • Local Institution - 148
    Las Vegas, Nevada 89102, United States
  • Local Institution - 188
    Berlin, New Jersey 08009, United States
  • Local Institution - 104
    New York, New York 10017, United States
  • Local Institution - 160
    New York, New York 10035, United States
  • Local Institution - 157
    New York, New York 10036, United States
  • Local Institution - 108
    Rochester, New York 14623, United States
  • Local Institution - 113
    Staten Island, New York 10314-1607, United States
  • Local Institution - 176
    Hickory, North Carolina 28601, United States
  • Local Institution - 163
    Independence, Ohio 44131, United States
  • Local Institution - 179
    Eugene, Oregon 97403, United States
  • Local Institution - 128
    Austin, Texas 78754, United States
  • Local Institution - 190
    Fort Worth, Texas 76104, United States
  • Local Institution - 180
    Houston, Texas 77074, United States
  • Local Institution - 103
    Irving, Texas 75062-2757, United States
  • Local Institution - 172
    Richardson, Texas 75080, United States
  • Local Institution - 159
    Richmond, Texas 77407, United States
  • Local Institution - 140
    Rutland, Vermont 05701, United States
  • Local Institution - 101
    Bellevue, Washington 98007, United States
  • Local Institution - 306
    Sofia, Sofia-Grad 1202, Bulgaria
  • Local Institution - 309
    Sofia, Sofia-Grad 1463, Bulgaria
  • Local Institution - 302
    Kazanlak, Stara Zagora 6100, Bulgaria
  • Local Institution - 318
    Cherven Bryag, 5980, Bulgaria
  • Local Institution - 311
    Dupnitsa, 2600, Bulgaria
  • Local Institution - 316
    Kardzhali, 6600, Bulgaria
  • Local Institution - 304
    Novi Iskar, 1282, Bulgaria
  • Local Institution - 301
    Pleven, 5800, Bulgaria
  • Local Institution - 315
    Pleven, 5800, Bulgaria
  • Local Institution - 314
    Plovdiv, 4002, Bulgaria
  • Local Institution - 321
    Plovdiv, 4004, Bulgaria
  • Local Institution - 313
    Razgrad, 7200, Bulgaria
  • Local Institution - 312
    Sliven, 8800, Bulgaria
  • Local Institution - 305
    Sofia, 1113, Bulgaria
  • Local Institution - 319
    Sofia, 1408, Bulgaria
  • Local Institution - 307
    Sofia, 1510, Bulgaria
  • Local Institution - 303
    Sofia, 1680, Bulgaria
  • Local Institution - 317
    Targovishte, 7700, Bulgaria
  • Local Institution - 308
    Varna, 9020, Bulgaria
  • Local Institution - 310
    Vratsa, 3000, Bulgaria
  • Local Institution - 250
    Toyoake-shi, Aichi-ken 470-1168, Japan
  • Local Institution - 255
    Fukuoka, Fukuoka 819-0037, Japan
  • Local Institution - 257
    Shirakawa-shi, Fukushima 961-0021, Japan
  • Local Institution - 254
    Karatsu-shi, Saga-ken 847-0031, Japan
  • Local Institution - 253
    Meguro-ku, Tokyo 1540012, Japan
  • Sangenjaya Neurology- Psychosomatic Clinic
    Setagaya-ku, Tokyo 1540004, Japan
  • Local Institution - 256
    Shinjuku-ku, Tokyo-To 162-0843, Japan
  • Local Institution - 403
    Belgrade, 101421, Serbia
  • Local Institution - 402
    Belgrade, 11000, Serbia
  • Local Institution - 405
    Belgrade, 11000, Serbia
  • Local Institution - 411
    Gornja Toponica, 705631, Serbia
  • Local Institution - 414
    Kovin, 26220, Serbia
  • Local Institution - 404
    Kovin, 306041, Serbia
  • Local Institution - 401
    Kragujevac, 34 000, Serbia
  • Local Institution - 406
    Kragujevac, 34 000, Serbia
  • Local Institution - 407
    Kragujevac, 34 000, Serbia
  • Local Institution - 408
    Kragujevac, 34 000, Serbia
  • Local Institution - 410
    Novi Kneževac, 23330, Serbia
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Mar 2026, 48 months.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 48 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Mar 31, 2022
StartActual
Mar 7, 2022
Primary completionActual
Mar 25, 2026
CompletionActual
Mar 25, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05304767
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Mar 7, 2022
Primary completion
Mar 25, 2026
Completion
Mar 25, 2026
Last update
Jul 31, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion